Wednesday, November 27, 2013 5:41:58 AM
U.S. listed Biota issued a press release announcing vapendavir would only advance into Phase-3 testing with a partner. I'm not sure how I'm privy to material information but I was told about this by Aussie management 9 months prior. Vapendavir actually achieved it's clinical Phase-2B endpoint within the HRV indication (common cold) by reducing the duration of cold symptoms in asthmatics. The problem is the compound increased the severity of symptoms in patients on the active drug. Patients in the real world setting won't visit the doctor seeking a medication that makes them feel worse to get better quickly. The chances of large pharma licensing this drug is about zero. Regardless this is the only follow-up compound, to laninamivir, within the BOTA pipeline.
A look at the R&D section of the Biota website tells investors where their money is being spent. Or does it? The preclinical antibiotic program hasn't produced a candidate in a couple years. Yet BOTA used it as an excuse to take a $2.9M charge. Note there's no mention of how many heads will be cut or where. Don't expect it to happen in Georgia.
The RSV program link on the Biota website offers the "Biota solution". Identical to their "Biota [antibiotic] solution". A description of a class of drug without mention of a pre-clinical candidate after years of waiting. The RSV program will be the next bogus charge against earnings the company takes.
Recent VXRT News
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/30/2024 12:00:00 PM
- Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:16:00 PM
- Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:01:00 PM
- Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 • GlobeNewswire Inc. • 08/02/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 10:10:10 AM
- Vaxart Provides Business Update • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 10:02:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:03:24 AM
- Vaxart Announces $40 Million Underwritten Offering of Common Stock • GlobeNewswire Inc. • 06/13/2024 11:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:26:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:36:53 PM
- Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 06/13/2024 08:15:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:38:42 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/23/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:03:43 PM
- Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 08:01:00 PM
- U.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed Reactions • IH Market News • 05/13/2024 11:10:27 AM
- Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM